Published in Drug Alcohol Depend on July 31, 2007
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend (2010) 1.01
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health (2009) 0.98
Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis (2011) 0.95
Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health (2013) 0.95
Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine (2010) 0.91
Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. World J Gastroenterol (2016) 0.88
Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health (2011) 0.80
Alcohol consumption and liver disease in Australia: a time series analysis of the period 1935-2006. Alcohol Alcohol (2013) 0.77
Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. Aust N Z J Public Health (2014) 0.75
Initial results of efficacy and safety of Sofosbuvir among Pakistani Population: A real life trial - Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS). Pak J Med Sci (2017) 0.75
The role of Aboriginal community attachment in promoting lifestyle changes after hepatitis C diagnosis. Health Psychol Open (2015) 0.75
Projections of the current and future disease burden of hepatitis C virus infection in Malaysia. PLoS One (2015) 0.75
Estimating the number of people who inject drugs in Australia. BMC Public Health (2017) 0.75
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Cancer incidence before and after kidney transplantation. JAMA (2006) 4.77
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst (2010) 4.57
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol (2009) 4.36
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Ethical challenges and responses in harm reduction research: promoting applied communitarian ethics. Drug Alcohol Rev (2005) 4.02
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Under-reporting of alcohol consumption in household surveys: a comparison of quantity-frequency, graduated-frequency and recent recall. Addiction (2004) 3.76
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
Increasing the benefits and reducing the harms of prescription opioid analgesics. Drug Alcohol Rev (2011) 3.35
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis (2004) 3.20
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention. Am J Bioeth (2012) 2.93
Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J (2006) 2.93
Concerns about injectable naltrexone for opioid dependence. Lancet (2011) 2.92
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology (2009) 2.66
Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS (2010) 2.65
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol (2003) 2.65
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst (2003) 2.65
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology (2002) 2.51
Counting the cost: estimating the number of deaths among recently released prisoners in Australia. Med J Aust (2011) 2.49
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet (2004) 2.43
Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS (2010) 2.43
How effective are short message service reminders at increasing clinic attendance? A meta-analysis and systematic review. Health Serv Res (2011) 2.42
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol (2008) 2.39
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS (2007) 2.27
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction (2005) 2.24
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 2.24
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend (2009) 2.20
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS (2005) 2.10
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05
A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction (2009) 2.03
Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. Hepatology (2008) 2.03
Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2009) 2.02
C-terminal-binding protein directly activates and represses Wnt transcriptional targets in Drosophila. EMBO J (2006) 2.01
Maternal bereavement during pregnancy and the risk of stillbirth: a nationwide cohort study in Sweden. Am J Epidemiol (2013) 1.99
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J (2006) 1.97
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology (2009) 1.91
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology (2011) 1.89
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol (2011) 1.88
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA (2002) 1.88
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis (2007) 1.87
Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.79
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis (2009) 1.79
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Young women engaged in sex work in Phnom Penh, Cambodia, have high incidence of HIV and sexually transmitted infections, and amphetamine-type stimulant use: new challenges to HIV prevention and risk. Sex Transm Dis (2011) 1.74
Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis (2012) 1.74
Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology (2014) 1.73
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol (2009) 1.70
Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol (2008) 1.69
NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology (2005) 1.67
High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health (2007) 1.67
Subcutaneous emphysema in cavitary pulmonary tuberculosis without pneumothorax or pneumomediastinum. Lung India (2012) 1.67
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol (2008) 1.64
Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy (2010) 1.64
Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol (2007) 1.63
Use of viral load to negotiate condom use among gay men in Sydney, Australia. AIDS Behav (2009) 1.62
Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol (2009) 1.61